Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab - Wikidata - wikimedia - TriplyDB

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

http://www.wikidata.org/entity/Q28260452

about

Diagnosis and management of catastrophic antiphospholipid syndrome.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Vascular endothelial cell function in catastrophic antiphospholipid syndrome: a case report and review of the literature.Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.Antiphospholipid syndrome in renal transplantation.36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature.Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report.Difficult clinical situations in the antiphospholipid syndrome.The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome.Microangiopathic antiphospholipid antibody-associated syndrome in a pregnant lady.Defective complement inhibitory function predisposes to renal disease.The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis.Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy.Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway.Top 10 clinical research developments in antiphospholipid syndrome.The expanding role of therapeutic antibodies.Antiphospholipid syndrome: an update.Rheumatologic emergencies.Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.Treatment of catastrophic antiphospholipid syndrome Myeloid Populations in Systemic Autoimmune Diseases.Emerging Therapies in Antiphospholipid Syndrome.Endothelial cells: source, barrier, and target of defensive mediators.Complement in ANCA-associated vasculitis: mechanisms and implications for management.Pathogenesis and management of antiphospholipid syndrome.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor.Circulating anti-beta2-glycoprotein I antibodies are associated with endothelial dysfunction, inflammation, and high nitrite plasma levels in patients with intermittent claudication.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Stratification of responders towards eculizumab using a structural epitope mapping strategy.All Things Complement.Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome.Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.Diagnosis and management of the antiphospholipid syndrome.

P2860

Q30235356-2049448F-C411-476F-9BAD-6F3F06B5D815 Q30276550-8EEF2B04-DF7E-41FC-8559-640B9B166916 Q33403225-0F56358A-0EF8-4E3D-87F3-4E23A2C6290F Q33403607-D858D3DF-562D-48B4-A4AE-2449DFEB5CA5 Q33408341-A62F0CAF-5403-4FAA-A3CD-46F955C116D7 Q33408360-3ED1D15E-00A0-4B9D-8F0A-E4BF91B80436 Q33413394-E0F6D65D-2F85-4DC1-B2FC-C2CBFCB79F7C Q33418663-777EDFB2-72F3-4292-BB2E-E59060CE8162 Q33419171-E0840F8B-AC59-4695-9675-4223C665B4BD Q33421814-5FB414A6-D95C-499A-8C81-849363690638 Q33431097-427F682E-EAB3-47EE-97BC-63B36E6A9203 Q33435712-840D6A33-1347-4CEF-BFEA-08E8B875735D Q34465747-93B8AF82-8815-450A-9595-B058832FD04F Q35057817-32610050-2D74-419F-AD78-63B78988057D Q35621012-CAC4B242-B6E2-4C83-9A1D-D3A109D19FFA Q35680817-A83187C9-6442-4227-95D1-9FCB7871A792 Q36879113-E18B101A-E49D-451D-AEC6-07B62BD520A1 Q37349421-3835024D-FAD8-41E4-B200-2D17F7FAE84D Q38135335-E838FB18-FCE8-4518-B1C5-EF5F36F24C0B Q38182645-71072655-09B5-4B96-9027-A7312D84F7D8 Q38410376-4523502B-BBBC-44BD-A09A-35D54FC55B5B Q38534478-E44FE795-05E1-4441-96DC-9BB1E9F00802 Q38657043-0BCA389D-AC07-4A2A-9D0F-96987FC03DE8 Q38718092-9DA5C2A7-2B12-477D-8FF2-5FF94127577A Q38755260-6A51F72C-BB64-46F1-98D5-9B4B180D94A3 Q38772739-819EF8F5-4D59-4BC4-9167-2EE45CA3C428 Q38782057-D8B3CD0C-73CB-4AF9-A1D0-F43B02C251C2 Q38991026-675695F3-FABC-4470-8F98-A5A6C832A96A Q39186343-D24E5DE7-D999-44D5-8067-625428BB322E Q39198671-12AC174A-8F00-4AA8-8DE8-587E012F493B Q39218839-0F43BBD0-8F8B-42AD-972F-23B15430CACC Q41211826-929A4D77-C6C3-4BD1-A46C-D20226892462 Q41989452-889F19E4-C540-41D1-B43C-488B09216D96 Q42086661-B53572D0-2E60-49CE-9401-3C7EC8F082ED Q42364725-929853D9-3134-4FD0-A996-8A2EAC496764 Q42386506-31FCEA65-1BE4-42B9-A1E9-4A18182AB15C Q42674523-3229C366-5494-4270-9316-72E25EC3C48F Q45857473-303259C3-7E3F-483D-9FB0-7E6EB303827F Q47640137-8FE29B2B-FA1C-45D1-AC75-2B829862F992 Q47982275-B6CF7D7A-24DF-4D32-AC44-B61068B97A53

P2860

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

http://www.wikidata.org/entity/Q28260452

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Brief report: induction of sus ...... nal complement with eculizumab

@ast

Brief report: induction of sus ...... nal complement with eculizumab

@en

Brief report: induction of sus ...... nal complement with eculizumab

@nl

type

label

Brief report: induction of sus ...... nal complement with eculizumab

@ast

Brief report: induction of sus ...... nal complement with eculizumab

@en

Brief report: induction of sus ...... nal complement with eculizumab

@nl

prefLabel

Brief report: induction of sus ...... nal complement with eculizumab

@ast

Brief report: induction of sus ...... nal complement with eculizumab

@en

Brief report: induction of sus ...... nal complement with eculizumab

@nl

P1433

Q28260452-D448E863-F3D0-47CF-B5D5-FC1515E70A35

P1476

Q28260452-9BCD49B0-EBD1-4074-86FE-1FDC7498272D

P2093

Q28260452-52486CCC-D09A-4AAF-9BCE-0EFE8CBA5CB7

Q28260452-C4EB7D46-EC10-4D01-A248-D6E9C659F8A5

Q28260452-C72024B0-EF8C-4267-BD08-15D916BF46B9

P2860

Q28260452-0689ECDE-677C-4BD0-808D-5D0A5F37F1D6

Q28260452-0C34BD0B-BD93-4203-B7EE-5F0A73073B55

Q28260452-2B08CE09-DE2A-413B-9647-4AC17AE7FE73

Q28260452-363570AC-76A2-4293-8C09-4BC55A447A83

Q28260452-3B4865FA-6CE8-4158-8E4D-F1B5AB02D9D9

Q28260452-58749926-0650-4998-99FA-B8F28E98CA51

Q28260452-6C39C149-F62A-4336-A6F5-ADFFE12665DB

Q28260452-A4425615-A3CD-4E58-98E1-887B2A561CB3

Q28260452-C52CB6B4-FDA5-4957-91A7-A818ACB600CC

Q28260452-CA8C863D-F73C-45FB-BF63-4C97A6AF07CB

P304

Q28260452-1E4A0850-0EA7-4E68-B82F-7D4828A2FFEA

P31

Q28260452-26C835F9-FD09-4EF6-9929-9F39D7C69D0F

P3181

Q28260452-D6C5C611-E1DA-4D1E-A50B-85C4963278A0

P356

Q28260452-91B2E1C5-2973-410C-BC12-B3C385E0B766

P407

Q28260452-F1BBC6B8-A79E-4B2C-B3C0-8B1E2962A827

P433

Q28260452-D56BCDB2-480D-46DD-97AE-145E74F128DF

P478

Q28260452-9CDB8415-6AEC-49E1-AC1D-31C673868E05

P50

Q28260452-1930770F-0F54-43F1-9095-491527BF872B

P577

Q28260452-FEE55055-BB60-488F-AE3D-E6E6F6816110

P5875

Q28260452-63C20DC8-F747-45EB-9D5D-D7F32193DD75

P698

Q28260452-30D74CCD-FD47-4C37-B7C4-58BC331874A1

P921

Q28260452-AE1A0F86-F191-45AF-9DCA-32E19000D33F

P3181

P356

P1433

Arthritis and Rheumatism

P1476

Brief report: induction of sus ...... nal complement with eculizumab

@en

P2093

Danieli Andrade

http://www.w3.org/2001/XMLSchema#string

Iuliana Shapira

http://www.w3.org/2001/XMLSchema#string

Jane E Salmon

http://www.w3.org/2001/XMLSchema#string

P2860

Eculizumab and renal transplantation in a patient with CAPS

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

Relapsing catastrophic antiphospholipid syndrome: report of three cases.

Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degen

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature.

Pathogenic role of antiphospholipid antibodies

Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment.

Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors.

P304

2719-2723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2142246

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/ART.34440

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221851493

http://www.w3.org/2001/XMLSchema#string

P698

22354668

http://www.w3.org/2001/XMLSchema#string

P921

catastrophic antiphospholipid syndrome